[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
P WernerC NeumannM EiberH J WesterMargret SchotteliusPublished in: EJNMMI research (2020)
[99mTc]Tc-PSMA-I&S-SPECT/CT was useful in PSMA-targeted imaging of PCa at various clinical stages. At low PSA levels (< 4 ng/ml), detection rates of [99mTc]Tc-PSMA-I&S-SPECT/CT in BCR are clearly inferior to data reported for PET-imaging and should thus only be considered for lesion detection if imaging with PET is unavailable. However, at higher PSA levels (> 4 ng/ml) [99mTc]Tc-PSMA-I&S-SPECT/CT provides high detection rates in BCR. [99mTc]Tc-PSMA-I&S-SPECT/CT can also be used for primary staging and for restaging of advanced recurrent PCa. However, further studies are needed to assess the clinical value in these indications.
Keyphrases
- pet ct
- positron emission tomography
- pet imaging
- prostate cancer
- image quality
- dual energy
- computed tomography
- contrast enhanced
- high resolution
- radical prostatectomy
- acute lymphoblastic leukemia
- loop mediated isothermal amplification
- label free
- magnetic resonance
- drug delivery
- mass spectrometry
- cancer therapy
- big data